The treatment of multiple sclerosis has made enormous progress thanks to highly effective disease-modifying therapies, in particular anti-CD20 antibodies. For most newly diagnosed patients, a life without disability is realistic. However, the focus is now shifting from preventing acute relapses to combating the insidious progression of disability. New approaches target cellular mechanisms in the CNS and the promotion of remyelination.
Autoren
- Dr. Ulf Blanke
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
You May Also Like
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- SURPASS-CVOT
Tirzepatide versus Dulaglutide in T2D with ASCVD
- Secondary prevention after ACS: individually optimized lipid management
Trend towards early combination therapy and new strategies for lowering Lp(a)
- Pediatric Brain Tumors
Psychiatry versus Neuro-Oncology: Diagnostic Pitfalls
- What the latest studies on the entire EF spectrum mean for clinical practice
Heart Failure – The 2026 Evidence Update
- Acute ischemic stroke
Alteplase and Tenecteplase Are on the Same Level
- CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment
SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes
- Wearables: screening via smartwatch?